Abstract:Background and Aim Treatment with immune checkpoint inhibitors (ICIs) for hepatocellular carcinoma (HCC) prior to liver transplantation (LT) has been reported; however, ICIs may elevate the risk of allograft rejection and impact other clinical outcomes. This study aims to summarize the impact of ICI use on post-LT outcomes. Materials and Methods In this individual patient data meta-analysis, we searched databases to identify HCC cases treated with ICIs before LT, detailing allograft rejection, HCC recurrence, and overall survival. We performed Cox regression analysis to identify risk factors for allograft rejection. Results Among 91 eligible patients, with a median (interquartile range [IQR]) follow-up of 690.0 (654.5) days, there were 24 (26.4%) allograft rejections, 9 (9.9%) HCC recurrences, and 9 (9.9%) deaths. Age (adjusted hazard ratio [aHR] per 10 years=0.72, 95% confidence interval [CI]=0.53, 0.99, P=0.044) and ICI washout time (aHR per 1 week=0.92, 95% CI=0.86, 0.99, P=0.022) were associated with allograft rejection. The median (IQR) washout period for patients with ≤20% probability of allograft rejection was 94 (196) days. Overall survival did not differ between cases with and without allograft rejection (log-rank test, p=0.2). Individuals with HCC recurrence had fewer median (IQR) ICI cycles than those without recurrence (4.0 [1.8]) vs. 8.0 [9.0]); p=0.025). The proportion of patients within Milan post-ICI was lower for those with recurrence vs. without (16.7% vs. 65.3%, p=0.032) Conclusion Patients have acceptable post-LT outcomes after ICI therapy. Age and ICI washout length relate to the allograft rejection risk, and a 3-month washout may reduce it to that of patients without ICI exposure. Number of ICI cycles and tumor burden may affect recurrence risk. Large prospective studies are necessary to confirm these associations. Impact and implications This systematic review and individual patient data meta-analysis of 91 patients with hepatocellular carcinoma and immune checkpoint inhibitors use prior to liver transplantation suggests acceptable overall post-transplant outcomes. Older age and longer immune checkpoint inhibitor washout period have a significant inverse association with the risk of allograft rejection. A 3-month washout may reduce it to that of patients without ICI exposure. Additionally, a higher number of immune checkpoint inhibitor cycles and tumor burden within Milan criteria at the completion of immunotherapy may predict a decreased risk of hepatocellular carcinoma recurrence, but this observation requires further validation in larger prospective studies. Code for International Prospective Register of Systematic Reviews (PROSPERO) CRD42023494951.

Withdrawn: Acute Rejection Was Observed in a Combination Therapy of CTLA-4 and PD-1 Inhibitors Before Liver Transplantation: A Case Report and Literature Review

Efficacy of Ctla4-Ig in Preventing Acute Rejection of Fully Allogeneic Heart Allografts in Sensitized Recipients

Preliminary evaluation of immune checkpoint inhibitors as a salvage treatment of tumor recurrence after liver transplantation for hepatocellular carcinoma

An Efficient Combination Immunotherapy for Antitumor Immunity Without Accelerating Cardiac Allograft Rejection.

Risk of transplant rejection associated with ICIs prior to liver transplantation in HCC: A multicenter retrospective study

Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials

Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review

Prognosis after Liver Transplantation in Patients Treated with Anti-Pd-1 Immunotherapy for Advanced Hepatocellular Carcinoma: Case Series.

Neoadjuvant programmed cell death 1 inhibitor before liver transplantation for HCC is not associated with increased graft loss

Programmed death receptor(PD)-1 monoclonal antibody-induced acute immune hepatitis in the treatment ;of recurrent hepatocellular carcinoma after liver transplantation:a case report

A Patient With Failed Liver Transplantation After the Use of PD-1 Blockade Combined With Lenvaxen

Prior to ABOi liver transplant with PD-1 inhibitor in patients with hepatocellular carcinoma: A case report

Pre-transplant Use of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma: A Multicenter, Retrospective Cohort Study

Case report: Predictability of clinical response and rejection risk after immune checkpoint inhibition in liver transplantation

Pretransplant immunotherapy increases acute rejection yet improves survival outcome of HCC patients with MVI post-liver transplantation

Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: A multicenter, retrospective cohort study

Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons

When Immunotherapy Meets Liver Transplantation for Hepatocellular Carcinoma:A Bumpy but Promising Road

Fatal graft-versus-host disease in recipient with pretransplant exposure to immune checkpoint inhibitors and donor-dominant one-way HLA matching after liver transplantation: A case report

Impact of Pre-Transplant Immune Checkpoint Inhibitor Use on Post-Transplant Outcomes in HCC: A Systematic Review and Individual Patient Data Meta-Analysis

Immunotherapy and Transplantation for Hepatocellular Carcinoma